The Role of Ganciclovir for the Management of Cytomegalovirus Retinitis in HIV Patients: Pharmacological Review and Update on New Developments
OBJECTIVE: To review the pharmacology and pharmacokinetics of intravenous, oral and intraocular ganciclovir, and to discuss the role of these various formulations in the management of cytomegalovirus (CMV) retinitis in AIDS patients.
Main Authors: | Alice Tseng, Michelle Foisy |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
1996-01-01
|
Series: | Canadian Journal of Infectious Diseases |
Online Access: | http://dx.doi.org/10.1155/1996/780831 |
Similar Items
-
Presumed neonatal cytomegalovirus retinitis treated with intravenous ganciclovir
by: A Suganya, et al.
Published: (2020-01-01) -
Initial intravitreal injection of high-dose ganciclovir for cytomegalovirus retinitis in HIV-negative patients
by: Zhuyun Qian, et al.
Published: (2018-12-01) -
Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant
by: C. Muccioli, et al.
Published: (2000-07-01) -
Comparison of intravitreal ganciclovir monotherapy and combination with foscarnet as initial therapy for cytomegalovirus retinitis
by: Jing-Jing Fan, et al.
Published: (2018-10-01) -
Effect of individualized therapy for AIDS patients with cytomegalovirus retinitis in intravitreal ganciclovir injections
by: Lian-Yong Xie, et al.
Published: (2019-08-01)